We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Abbott Highlights Rapid Diagnostic Platforms to Complement Centralized RT-PCR Testing at ECCMID 2022

By LabMedica International staff writers
Posted on 26 Apr 2022
Print article
Image: ID NOW Molecular Platform (Photo courtesy of Abbott)
Image: ID NOW Molecular Platform (Photo courtesy of Abbott)

Abbott (Lake Forest, IL, USA) participated in ECCMID 2022 where it highlighted its range of rapid diagnostic platforms that complement centralized RT-PCR testing as well as empowers labs to efficiently and cost-effectively extend their impact throughout hospitals.

Abbott’s product portfolio exhibited at ECCMID 2022 included ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The company’s ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing healthcare professionals to make effective clinical decisions sooner. Abbott demonstrated its Panbio COVID-19 Ag Rapid Test Device that can identify potentially contagious patients with or without symptoms in 15 minutes alongside its Panbio COVID-19 IgG/IgM Rapid Test Device for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 in human serum, plasma, venous and fingerstick whole blood.

In addition, Abbott demonstrated its Afinion CRP rapid in vitro diagnostic test for the quantitative determination of C-reactive protein (CRP) in human blood in three minutes. Afinion CRP helps reduce diagnostic uncertainty and guides antibiotic decision-making during the patient’s visit. A significantly increased CRP result may indicate the need for immediate antibiotic treatment. CRP Point of care testing has been shown to reduce antibiotic prescribing by more than 60% if combined with communication training for general practitioners. The test runs on Abbott’s Afinion2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care. With the Afinion System, there’s no need to send patients to the lab or spend time tracking down their results.

Related Links:
Abbott 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
Urine Drug Test
Instant-view Propoxyphene Urine Drug Test
New
DVT/PE Test
VIDAS D-DIMER EXCLUSION II

Print article

Channels

Molecular Diagnostics

view channel
Image: The DNA sequencing method indentifies the bacterial causes of infections to determine the most effective antibiotics for treatment (Photo courtesy of Shutterstock)

New DNA Test Diagnoses Bacterial Infections Faster and More Accurately

Antimicrobial resistance has emerged as a significant global health threat, causing at least one million deaths annually since 1990. The Global Research on Antimicrobial Resistance (GRAM) Project warns... Read more

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Sekisui Diagnostics UK Ltd.